Business

ADOCIA Announces its Financial Calendar for 2026

LYON, France, December 18, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026.

articleAdocia SaDecember 18, 20252/company/adocia-sa/news/adocia-announces-its-financial-calendar-for-2026-1
ADOCIA Announces its Financial Calendar for 2026

About this update from Adocia Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/cd3a6787dcf1e38b709833b06b1c114a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_KvY3B24TinkAO8jagH_8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cd3a6787dcf1e38b709833b06b1c114a","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/R.I24myWIpGBP10ru5KfVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/cd3a6787dcf1e38b709833b06b1c114a","width":1200,"height":485}},"lazy":false},{"type":"text","content":"LYON, France, December 18, 2025--(BUSINESS WIRE)--Regulatory News:","length":71,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026.","length":256,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;white-space:nowrap;","val":[{"type":"text","content":"February 24, 2026","length":17,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","val":[{"type":"text","content":" ","length":6,"tagName":"p"}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;","val":[{"type":"text","content":"Publication of revenue for Q4 2025","length":34,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;white-space:nowrap;","val":[{"type":"text","content":"April 21, 2026","length":14,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","val":[{"type":"text","content":" ","length":6,"tagName":"p"}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;","val":[{"type":"text","content":"Publication of 2025 financial statements","length":40,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;padding-left:0.0px;white-space:nowrap;","val":[{"type":"text","content":"May 12, 2026","length":12,"tagName":"p","attribs":{}}]...

More updates from Adocia Sa

biopharmaceutical companyEuronext Parisfinancial statementsfinancial calendartreatment of diabetesthe company